Keyphrases
Randomized Placebo-controlled Trial
100%
Atorvastatin
100%
Cirrhosis
100%
Portal Hypertension
42%
Lipidomics
42%
Inflammatory Markers
28%
Complication Risk
28%
Anti-inflammatory Effect
28%
Liver Complications
28%
Hospital Admission
14%
High Risk
14%
Inflammation
14%
Treatment Duration
14%
Placebo
14%
Lipids
14%
Mortality Risk
14%
Between-group
14%
Statins
14%
Patient-completed
14%
L-selectin
14%
Minor Effect
14%
Matrix metalloproteinase-2 (MMP-2)
14%
Splanchnic Hemodynamics
14%
Portal Pressure
14%
MELD Score
14%
Liver-related Mortality
14%
Antifibrotic
14%
Induced Minor
14%
CD62
14%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Atorvastatin
100%
Liver Cirrhosis
100%
Portal Hypertension
42%
Inflammation
14%
Tumor Necrosis Factor
14%
Controlled Clinical Trial
14%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
Anti-Inflammatory Drug
14%
L Selectin
14%
Gelatinase A
14%
Antiinflammatory Activity
14%
End Stage Liver Disease
14%